Decentralized Clinical Trials: How Research Can Reach More People

What makes a clinical trial decentralized?

An ordinary clinical trial often asks participants to travel repeatedly to a central hospital or research facility. In a study with decentralized elements, certain activities may occur in participants' homes, community settings, local laboratories, or through secure digital communication. The protocol and applicable requirements still define what investigators may do and how information is collected.

The FDA's September 2024 final guidance addresses recommendations for decentralized trial elements. It describes possibilities such as telehealth visits, remote personnel in a participant's home, and care from local providers. It does not say a remote location eliminates the need for proper sponsorship, safety oversight, product accountability, or legally required review.

Why decentralization matters for access

Geography, travel costs, work schedules, disability, and caregiver responsibilities can all make research participation harder. Decentralized designs can reduce certain barriers and allow people who live far from academic centers to contribute. The potential benefit is not only convenience: more inclusive recruitment can improve whose experiences are represented in research evidence.

However, moving procedures outside a clinic raises practical questions. Does a local provider understand the protocol? Can adverse events be reported quickly? Are measurements consistent? Who ships and controls investigational supplies? How are privacy, consent changes, lost connectivity, and unexpected results handled? The answers differ by project and cannot be solved by naming a video-conferencing application.

The distinction between distributed and self-directed research

A decentralized trial is a design feature, not a legal category that confers new authorization. A community study may analyze voluntarily shared observations without assigning interventions, or it may actively assign treatments. Those designs are different in both scientific inference and regulatory analysis. ClinicalTrials.gov distinguishes observational studies from interventional clinical trials on that basis.

Citizen scientists may contribute ideas, observations, and data stewardship to either kind of project. A sponsor still needs an appropriate governance model for activities that require it. Better public infrastructure could help small organizations use lawful decentralized methods without losing clear lines of responsibility.

Building an accountable decentralized future

A participant-centered architecture can separate consent records, identity custody, encrypted research observations, and public aggregate findings. Study-specific access tokens can express access policy, but a token alone does not make information anonymous or legally protected. The rules for onward sharing and withdrawal need to be specified independently of the software.

The Right to Research initiative explores a model of shared research infrastructure informed by these issues. It does not claim an operational clinical trial or certified research database on this website. The objective is to make the future conversation more concrete: which activities can be distributed, who is responsible for them, and what should happen when a participant changes their mind?

Questions people ask